Vertex Pharmaceuticals (VRTX) investor relations material

Executive summary

• Q1 2026 revenue grew 8% year-over-year to $2.99 billion, driven by strong cystic fibrosis (CF) therapies, new product launches such as ALYFTREK, CASGEVY, and JOURNAVX, and successful commercial execution.

• ALYFTREK surpassed $1 billion in cumulative revenue; CASGEVY exceeded 500 patient initiations and $43 million in Q1 sales; JOURNAVX reached over 1 million prescriptions and $29 million in Q1 revenue.

• Pipeline progress included positive Phase 3 interim data and BLA submission for povetacicept in IgA nephropathy, and regulatory milestones for ALYFTREK, TRIKAFTA, and CASGEVY.

• Diversification into new disease areas contributed over 25% of quarterly growth, with robust R&D and expansion in renal, pain, and diabetes portfolios.

• Cash, cash equivalents, and marketable securities totaled $13.0 billion at quarter-end, up from $12.3 billion at year-end 2025.

Financial highlights

• Total Q1 2026 revenue: $2.99 billion, up 8% year-over-year; CF products accounted for $2.92 billion.

• U.S. revenue increased 7% to $1.78 billion; ex-U.S. revenue rose 9% to $1.21 billion.

• Non-GAAP operating income: $1.31 billion (44% margin); GAAP operating income: $1.14 billion.

• Non-GAAP net income: $1.1 billion; GAAP net income: $1.0 billion; diluted GAAP EPS: $4.02; non-GAAP EPS: $4.47.

• Ended Q1 with $13.0 billion in cash and investments; $344 million deployed for share repurchases.

Outlook and guidance

• 2026 total revenue guidance reiterated at $12.95–$13.1 billion, with at least $500 million expected from non-CF products.

• Combined non-GAAP R&D, Acquired IPR&D, and SG&A expenses expected at $5.65–$5.75 billion; non-GAAP effective tax rate projected at 19.5–20.5%.

• Full-year gross margin expected just under 86%.

• Guidance includes continued investment in clinical development and commercialization, with immaterial impact from tariffs.

• Management expects cash flows and liquidity to fund operations for at least the next twelve months.